Free Newsletter
Shire surprises by tapping new CEO
Surprise! You're the next CEO. So said Shire to CFO Angus Russell (photo), who got an unexpected promotion to the company's top slot. The board moved present CEO Matt Emmens to non-executive chair, replacing James Cavanaugh, who retires in June. The changes won't take place until Cavanaugh's exit.
So who is Angus Russell? The 51-year old has been CFO at Shire since 1999, helping to usher the company through several mergers. Before that, he worked in finance, strategy, and marketing at several pharma companies, including AstraZeneca.
- check out Shire's statement
- read the report from MarketWatch
Related Articles:
New guard takes over Big Pharma. Report
Shire on lookout for acquisitions. Report
Shire to Massachusetts: Pass incentive bill now. Report
FDA approves Shire's new ulcerative colitis drug. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: